Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967732 | 0.87 | KMT2A (0.61) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL21419053 | 0.82 | KMT2A (0.46) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL21419159 | 0.76 | HTT (0.40) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL3370446 | 0.74 | KMT2A (0.58) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL28895677 | 0.74 | KMT2A (0.62) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL21139639 | 0.73 | KMT2A (0.36) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL2609312 | 0.72 | LMNA (0.44) | KMT2AMAPK1SMN1; SMN2MEN1LMNA | |
| SCHEMBL14920646 | 0.71 | KMT2A (0.56) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL10192289 | 0.71 | KMT2A (0.56) | KMT2AMAPK1GAASMN1; SMN2RAB9A | |
| SCHEMBL12248259 | 0.71 | CCR1 (0.35) | KMT2AMAPK1GAASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2019195159-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | KMT2A 4588/4885MAPK1 2393/4885GAA 4587/4885 |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | KMT2A 4588/4885MAPK1 2393/4885GAA 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.